FDA Issues Guidance Agenda for 2012
FDA has issued a list of planned draft and final guidance documents for release throughout 2012.
FDA has issued a list of planned draft and final guidance documents for release throughout 2012. There are about 50 such guidances planned. Below are a few highlights for the drug-manufacturing space.
In biopharmaceutics and biosimilarity:
- Food-Effect Bioavailability and Fed Bioequivalence Studies—Bioavailability and Bioequivalence Studies for Orally Administered Drug Products Submitted in New Drug Applications General Consideration
- Scientific Considerations in Demonstrating Biosimilarity To a Reference Product (draft already issued)
- Quality Considerations in Demonstrating Biosimilarity To a Reference Protein Product (draft already issued)
- Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 (draft already issued)
In combination products:
- Development of Drugs in Combination
In CGMPs and compliance:
- Control of Highly Potent Compounds
- Expiration Dating of Unit-Dose Repackaged Drugs: Compliance Policy Guide
- Importation of Active Pharmaceutical Ingredients (API) for Use in Human Drugs
In labeling, packaging, and supply chain:
- Naming, Labeling, and Packaging Practices to Reduce Medication Errors
- Securing the Drug Supply Chain—Standards for Tracking and Tracing Prescription Drug Packages
- Drug Names and Dosage Forms
- Organ-Specific Warnings: Internal Analgesic, Antipyretic and Antirheumatic Drug Products for Over-the-Counter Human Use-Labeling of Products That Contain Acetaminophen
- Pediatric Information: Incorporating into Human Prescription Drug and Biological Products Labeling
In regulatory filings (electronic):
- Providing Regulatory Submissions in Electronic Format – General Considerations
- Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications
- Providing Regulatory Submissions in Electronic Format – Study Data
- Providing Regulatory Submissions in Electronic Format – Standardized Study Data
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
